133 related articles for article (PubMed ID: 8970634)
21. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection.
Thomas H; Maillet F; Letourneur D; Jozefonvicz J; Fischer E; Kazatchkine MD
Mol Immunol; 1996; 33(7-8):643-8. PubMed ID: 8760276
[TBL] [Abstract][Full Text] [Related]
22. Regulation of complement-mediated swine endothelial cell lysis by a surface-bound form of human C4b binding protein.
Mikata S; Miyagawa S; Iwata K; Nagasawa S; Hatanaka M; Matsumoto M; Kamiike W; Matsuda H; Shirakura R; Seya T
Transplantation; 1998 Feb; 65(3):363-8. PubMed ID: 9484752
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.
Dalmasso AP; Vercellotti GM; Platt JL; Bach FH
Transplantation; 1991 Sep; 52(3):530-3. PubMed ID: 1716798
[TBL] [Abstract][Full Text] [Related]
24. Transgenic mice designed to express human alpha-1,2-fucosyltransferase in combination of human DAF and CD59 to avoid xenograft rejection.
Liu B; Cheng C; Wu Y; Wei J; Li G; Ma T
Sci China C Life Sci; 2008 Mar; 51(3):199-204. PubMed ID: 18246307
[TBL] [Abstract][Full Text] [Related]
25. Targeting complement in therapy.
Kirschfink M
Immunol Rev; 2001 Apr; 180():177-89. PubMed ID: 11414360
[TBL] [Abstract][Full Text] [Related]
26. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice.
Byrne GW; McCurry KR; Kagan D; Quinn C; Martin MJ; Platt JL; Logan JS
Transplantation; 1995 Nov; 60(10):1149-56. PubMed ID: 7482724
[TBL] [Abstract][Full Text] [Related]
27. Reaction of complement with endothelial cells in a model of xenotransplantation.
Dalmasso AP; Platt JL; Bach FH
Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):31-5. PubMed ID: 1718641
[TBL] [Abstract][Full Text] [Related]
28. High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection.
Cowan PJ; Somerville CA; Shinkel TA; Katerelos M; Aminian A; Romanella M; Tange MJ; Pearse MJ; d'Apice AJ
Transplantation; 1998 Mar; 65(6):826-31. PubMed ID: 9539095
[TBL] [Abstract][Full Text] [Related]
29. Expression of human soluble complement receptor 1 by a pig endothelial cell line inhibits lysis by human serum.
Manzi L; Montaño R; Abad MJ; Arsenak M; Romano E; Taylor P
Xenotransplantation; 2006 Jan; 13(1):75-9. PubMed ID: 16497215
[TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection.
Niemann H; Verhoeyen E; Wonigeit K; Lorenz R; Hecker J; Schwinzer R; Hauser H; Kues WA; Halter R; Lemme E; Herrmann D; Winkler M; Wirth D; Paul D
Transplantation; 2001 Dec; 72(12):1898-906. PubMed ID: 11773886
[TBL] [Abstract][Full Text] [Related]
31. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity.
Lilienfeld BG; Crew MD; Forte P; Baumann BC; Seebach JD
Xenotransplantation; 2007 Mar; 14(2):126-34. PubMed ID: 17381687
[TBL] [Abstract][Full Text] [Related]
32. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.
Bergamaschini L; Gobbo G; Gatti S; Caccamo L; Prato P; Maggioni M; Braidotti P; Di Stefano R; Fassati LR
Clin Exp Immunol; 2001 Dec; 126(3):412-20. PubMed ID: 11737055
[TBL] [Abstract][Full Text] [Related]
33. Cross-species function of the pig C1 esterase inhibitor.
Koboyashi C; Matsunami K; Omori T; Nakahata K; Nakatsu S; Xu H; Gao C; Ihara Y; Fukuzawa M; Miyagawa S
Transplant Proc; 2006 Dec; 38(10):3321-2. PubMed ID: 17175261
[TBL] [Abstract][Full Text] [Related]
34. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.
Yasojima K; McGeer EG; McGeer PL
Brain Res; 1999 Jul; 833(2):297-301. PubMed ID: 10375708
[TBL] [Abstract][Full Text] [Related]
35. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
[TBL] [Abstract][Full Text] [Related]
36. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis.
Fukuta D; Miyagawa S; Yamada M; Matsunami K; Kurihara T; Shirasu A; Hattori H; Shirakura R
Xenotransplantation; 2003 Mar; 10(2):132-41. PubMed ID: 12588646
[TBL] [Abstract][Full Text] [Related]
37. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil adhesion and complement inhibition prolongs survival of cardiac xenografts in discordant species.
Zehr KJ; Herskowitz A; Lee PC; Kumar P; Gillinov AM; Baumgartner WA
Transplantation; 1994 Mar; 57(6):900-6. PubMed ID: 8154039
[TBL] [Abstract][Full Text] [Related]
39. Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies.
Schaapherder AF; Gooszen HG; te Bulte MT; Daha MR
Transplantation; 1995 Aug; 60(3):287-91. PubMed ID: 7645041
[TBL] [Abstract][Full Text] [Related]
40. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection.
Pruitt SK; Baldwin WM; Marsh HC; Lin SS; Yeh CG; Bollinger RR
Transplantation; 1991 Nov; 52(5):868-73. PubMed ID: 1949173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
